GlassScriptPhysician profile
Nefize Turan
NPI 1073008306
$19,165.67
in general payments reported to CMS, 2019-2025
16 companies · $7,985 in 2025
The $7,985 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.58 · 2021: $154 · 2022: $133 · 2023: $3,991 · 2024: $6,875 · 2025: $7,985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $13K · Food and Beverage: $5,076 · Education: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $13,155.47 |
| Food and Beverage | $5,075.89 |
| Education | $619.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $10,101.58 | 2023-2025 | Penumbra System, Benchmark, Indigo System |
| Stryker Corporation | $3,585.48 | 2025 | Surpass Evolve, Mild Device Kit, Optablate |
| Medical Device Business Services, INC. | $2,917.78 | 2024-2025 | Trufill, Embotrap, Pulsar Vascular Pulserider Aneurysm Neck Reconstruction Device |
| Medtronic, INC. | $860.63 | 2024-2025 | Pipeline, Solitaire X |
| Route 92 Medical, INC. | $294.25 | 2025 | |
| Depuy Synthes Sales INC. | $271.01 | 2024-2025 | Embotrap, Emboguard, Trufill |
| Ucb, INC. | $213.57 | 2023-2024 | Briviact |
| Rapid Medical LTD | $179.88 | 2025 | Tigertriever 17 Revascularization Device, Comaneci 17 |
| Balt USA, LLC | $177.56 | 2023 | |
| Qapel Medical INC | $134.24 | 2025 | |
| Merz Pharmaceuticals, LLC | $133.34 | 2022 | |
| Microvention, INC. | $91.09 | 2024-2025 | Web Aneurysm Embolization System, Stent, Lvis |
| Allergan, INC. | $77.42 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $77.00 | 2021 | |
| Portola Pharmaceuticals, LLC | $26.58 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $24.26 | 2025 | Spinraza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nefize Turan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.